Indicated for: prevention of atherothrombotic events
Route of administration: oral
Substance: triflusal (anticoagulant)
ATC: B01AC18 (Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin)
Dose adjustment may be needed in kidney disease.
This medicine may have important interactions with other medicines.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
This medicine may increase the risk of bleeding.
Triflusal is an antiplatelet medication used to prevent thrombotic events such as myocardial infarction and ischemic stroke. It works by inhibiting cyclooxygenase-1 (COX-1) activity and increasing prostacyclin levels, thereby reducing blood clot formation.
Triflusal is particularly indicated for patients with a high cardiovascular risk, serving as an alternative to aspirin for those who do not tolerate it well. It is used in the secondary prevention of strokes and other arterial thrombotic events.
Compared to aspirin, triflusal has a lower risk of gastrointestinal side effects and bleeding, making it a safer option for certain patient groups. However, its use should be carefully monitored, and the dosage should be adjusted based on the individual needs of the patient.
Price
Copayment
Patient
39.97 RON
19.99 RON
19.99 RON